Pharmaceutical giant Eli Lilly is set to report its Q2 results on August 8, with expectations of $10 billion in sales and $2.70 in adjusted earnings per share. Investors will be closely watching the performance of the company’s diabetes drug Mounjaro and weight-loss drug Zepbound. LLY stock has shown strong gains over the years, outperforming the S&P 500 consistently. Despite uncertainties in the macroeconomic environment, analysts are bullish on Eli Lilly’s future pipeline potential.
In the previous quarter, Eli Lilly reported revenue of $8.8 billion, driven by market share gains for drugs like Mounjaro, Verzenio, and Jardiance. Mounjaro saw a significant increase in sales, while the company’s adjusted gross margin also expanded. Looking ahead, Eli Lilly is expected to see further growth in sales, with Mounjaro and Verzenio sales projected to increase significantly. The company’s 2024 sales forecast shows a significant uptick from previous years, indicating strong growth potential.
Although Eli Lilly is poised to deliver a strong quarter, supply shortages may impact sales of some drugs in the current quarter. However, with the U.S. FDA stating that all doses of Eli Lilly’s weight-loss drugs are now available, a better sales picture is expected in Q3. Investors should keep an eye on how these developments will impact the company’s overall performance in the coming quarters.
While LLY stock may continue to see gains, it is important to look at how Eli Lilly’s peers are faring in comparison. By analyzing metrics that matter across industries, investors can gain valuable insights into the performance of similar companies. As Eli Lilly prepares to report its Q2 results, market watchers will be monitoring the company’s performance closely to assess its growth potential and investment opportunities in the pharmaceutical sector.
With expectations high for Eli Lilly’s Q2 results, investors are optimistic about the company’s future prospects. Strong sales growth driven by diabetes and obesity drugs is expected to fuel the company’s performance in the coming quarters. Despite supply shortages impacting sales in the current quarter, the availability of weight-loss drugs is expected to boost sales in the next quarter. Overall, Eli Lilly appears to be on track for another strong quarter, showcasing its potential for future growth and outperformance in the pharmaceutical industry.
